Covered recipient · General Payments record
MIRELIS ACOSTA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$14,256.60
129 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,540.00 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,400.00 | 4 |
| Food and Beverage | $2,316.60 | 120 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eisai Inc. | $7,623.21 | 13 |
| Merck Sharp & Dohme Corporation | $4,290.94 | 10 |
| E.R. Squibb & Sons, L.L.C. | $752.80 | 15 |
| Genentech USA, Inc. | $232.64 | 13 |
| Amgen Inc. | $221.52 | 14 |
| Janssen Pharmaceuticals, Inc | $155.65 | 9 |
| AbbVie Inc. | $153.70 | 8 |
| AstraZeneca Pharmaceuticals LP | $125.74 | 7 |
| GENZYME CORPORATION | $122.82 | 7 |
| PBG PUERTO RICO LLC | $113.95 | 7 |
| Bayer HealthCare Pharmaceuticals Inc. | $106.41 | 7 |
| Taiho Oncology, Inc. | $68.62 | 4 |
| Ipsen Biopharmaceuticals, Inc | $53.11 | 2 |
| Novartis Pharmaceuticals Corporation | $45.93 | 2 |
| Partner Therapeutics, Inc. | $43.79 | 2 |
| Eli Lilly Export S.A. Puerto Rico Branch | $30.68 | 2 |
| Astellas Pharma US Inc | $22.11 | 1 |
| Puma Biotechnology, Inc. | $20.32 | 1 |
| Exelixis Inc. | $16.52 | 1 |
| SANOFI-AVENTIS U.S. LLC | $16.05 | 1 |
| PFIZER INC. | $14.64 | 1 |
| BeiGene USA, Inc. | $13.94 | 1 |
| Pharmacyclics LLC, An AbbVie Company | $11.51 | 1 |
Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MIRELIS ACOSTA
NPI 1093961609 · CMS profile ID 992761
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAN JUAN, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1093961609?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MIRELIS ACOSTA, NPI 1093961609, CMS profile ID 992761. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093961609?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). MIRELIS ACOSTA, NPI 1093961609, CMS profile ID 992761. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093961609?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- MIRELIS ACOSTA, NPI 1093961609, CMS profile ID 992761, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1093961609?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
129 matching records · $14,256.60 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 129.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $19.90 | 07/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743066037 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.87 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713641165 | CMS |
| Eisai Inc. | $1,890.00 | 07/14/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751340613 | CMS |
| Amgen Inc. | $10.50 | 07/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741236189 | CMS |
| PBG PUERTO RICO LLC | $19.95 | 07/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743549629 | CMS |
| Janssen Pharmaceuticals, Inc | $16.05 | 07/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719316419 | CMS |
| Janssen Pharmaceuticals, Inc | $14.44 | 07/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719316423 | CMS |
| Amgen Inc. | $11.30 | 06/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741236201 | CMS |
| GENZYME CORPORATION | $18.14 | 06/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744013875 | CMS |
| AbbVie Inc. | $16.50 | 06/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721662631 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.56 | 06/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727936371 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.22 | 06/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727936363 | CMS |
| Genentech USA, Inc. | $17.79 | 06/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743066053 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.05 | 06/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713628813 | CMS |
| Genentech USA, Inc. | $15.88 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743066073 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727936355 | CMS |
| Taiho Oncology, Inc. | $14.30 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724402433 | CMS |
| Genentech USA, Inc. | $19.90 | 05/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743066031 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.14 | 05/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713623441 | CMS |
| BeiGene USA, Inc. | $13.94 | 05/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752947189 | CMS |
| AbbVie Inc. | $17.75 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721662627 | CMS |
| Amgen Inc. | $14.27 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741236191 | CMS |
| Amgen Inc. | $19.52 | 04/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741236179 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.00 | 04/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735765459 | CMS |
| E.R. Squibb & Sons, L.L.C. | $250.00 | 04/27/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753935804 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.33 | 04/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736436101 | CMS |
| GENZYME CORPORATION | $14.95 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744013855 | CMS |
| Janssen Pharmaceuticals, Inc | $20.00 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719316417 | CMS |
| Amgen Inc. | $20.18 | 04/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741236187 | CMS |
| AbbVie Inc. | $17.75 | 04/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721662625 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 03/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727936335 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.00 | 03/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736386651 | CMS |
| Partner Therapeutics, Inc. | $19.99 | 03/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747928709 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.95 | 03/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727936323 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.23 | 03/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727936327 | CMS |
| Merck Sharp & Dohme Corporation | $18.18 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747691193 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.77 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713624785 | CMS |
| Ipsen Biopharmaceuticals, Inc | $23.83 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741940891 | CMS |
| Merck Sharp & Dohme Corporation | $16.47 | 03/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747639727 | CMS |
| Janssen Pharmaceuticals, Inc | $16.52 | 03/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719316421 | CMS |
| Janssen Pharmaceuticals, Inc | $14.19 | 03/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719316411 | CMS |
| Puma Biotechnology, Inc. | $20.32 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750542433 | CMS |
| Partner Therapeutics, Inc. | $23.80 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747928707 | CMS |
| Eisai Inc. | $122.77 | 02/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751342295 | CMS |
| Eisai Inc. | $2,700.00 | 02/27/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751344727 | CMS |
| PBG PUERTO RICO LLC | $11.72 | 02/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743529215 | CMS |
| AbbVie Inc. | $20.00 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721662621 | CMS |
| Janssen Pharmaceuticals, Inc | $30.91 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719316407 | CMS |
| Eisai Inc. | $13.27 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751206165 | CMS |
| Eisai Inc. | $23.80 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751206171 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $272,928.82 | 41 |
| PY2024 | Principal investigator | $776,395.24 | 51 |
| PY2023 | Principal investigator | $1,189,320.31 | 53 |
| PY2022 | Principal investigator | $1,540,472.88 | 33 |
| PY2021 | Recipient | $1,910.15 | 2 |
| PY2021 | Principal investigator | $880,604.20 | 33 |
| PY2020 | Recipient | $708.70 | 1 |
| PY2020 | Principal investigator | $857,624.67 | 95 |
| PY2019 | Recipient | $11,257.00 | 3 |
| PY2019 | Principal investigator | $650,651.37 | 30 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
41 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $725.12 | 12/31/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults with Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1202534471 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,264.61 | 12/31/2025 | Non-covered Recipient Entity FDI Clinical Research | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P | No dispute reported | 06/30/2026 | 1232938254 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $63,061.31 | 12/17/2025 | Non-covered Recipient Entity FDI Clinical Research | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P | No dispute reported | 06/30/2026 | 1232938252 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,220.00 | 11/13/2025 | Non-covered Recipient Entity FDI Clinical Research | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926945 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 11/07/2025 | Non-covered Recipient Entity Fundacion de Investigacion de Diego | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222380618 |
| Principal investigator 1 | Exelixis Inc. | $1,867.30 | 11/07/2025 | Non-covered Recipient Entity Fundacion de Investigacion de Diego | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222380620 |
| Principal investigator 1 | Exelixis Inc. | $14,000.00 | 11/07/2025 | Non-covered Recipient Entity Fundacion de Investigacion de Diego | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222380622 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 11/07/2025 | Non-covered Recipient Entity Fundacion de Investigacion de Diego | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222380624 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 11/07/2025 | Non-covered Recipient Entity Fundacion de Investigacion de Diego | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors | No dispute reported | 06/30/2026 | 1222380626 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,700.00 | 11/03/2025 | Non-covered Recipient Entity FDI Clinical Research | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926773 |
| Principal investigator 1 | ABBVIE INC. | $4,500.00 | 10/20/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | No dispute reported | 06/30/2026 | 1202517451 |
| Principal investigator 1 | TOLMAR, INC. | $1,521.45 | 10/17/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A-EXT | No dispute reported | 06/30/2026 | 1237322324 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,750.00 | 10/15/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO, INC. | A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) | No dispute reported | 06/30/2026 | 1185547619 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $32,961.70 | 09/18/2025 | Non-covered Recipient Entity Fdi Clinical Research | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies | No dispute reported | 06/30/2026 | 1235997407 |
| Principal investigator 1 | ABBVIE INC. | $19,500.00 | 09/02/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | No dispute reported | 06/30/2026 | 1202507015 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $264.09 | 08/31/2025 | Non-covered Recipient Entity FDI Clinical Research | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P | No dispute reported | 06/30/2026 | 1232938256 |
| Principal investigator 1 | TOLMAR, INC. | $742.50 | 07/18/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A-EXT | No dispute reported | 06/30/2026 | 1237322217 |
| Principal investigator 1 | TOLMAR, INC. | $2,061.45 | 06/13/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A-EXT | No dispute reported | 06/30/2026 | 1237322209 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,045.40 | 06/13/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | Fruquintinib | No dispute reported | 06/30/2026 | 1223281234 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,965.00 | 05/28/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280384 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $750.00 | 05/28/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280386 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,514.47 | 05/15/2025 | Non-covered Recipient Entity Fdi Clinical Research | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1235997405 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 05/12/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223279388 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $13,631.97 | 04/28/2025 | Non-covered Recipient Entity Fundacion De Investigacion | A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy | No dispute reported | 06/30/2026 | 1236531120 |
| Principal investigator 1 | Organon Llc | $500.00 | 04/14/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | 8415-060 | No dispute reported | 06/30/2026 | 1173042250 |
| Principal investigator 1 | Organon Llc | $9,943.92 | 04/07/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | 8415-060 | No dispute reported | 06/30/2026 | 1173042244 |
| Principal investigator 1 | Organon Llc | $3,400.00 | 04/07/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | 8415-060 | No dispute reported | 06/30/2026 | 1173042246 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $7,548.84 | 03/21/2025 | Non-covered Recipient Entity Fundacion De Investigacion | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | No dispute reported | 06/30/2026 | 1236531116 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,375.00 | 03/05/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO | Fruquintinib | No dispute reported | 06/30/2026 | 1223276049 |
| Principal investigator 1 | TOLMAR, INC. | $765.00 | 02/21/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322031 |
| Principal investigator 1 | TOLMAR, INC. | $742.50 | 02/21/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322034 |
| Principal investigator 1 | TOLMAR, INC. | $2,500.00 | 02/21/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322037 |
| Principal investigator 1 | TOLMAR, INC. | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322040 |
| Principal investigator 1 | TOLMAR, INC. | $650.00 | 02/21/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322043 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,108.19 | 02/20/2025 | Non-covered Recipient Entity Fdi Clinical Research | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1235997409 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,434.00 | 02/11/2025 | Non-covered Recipient Entity Fundacion De Investigacion De Diego | A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1235997263 |
| Principal investigator 1 | TOLMAR, INC. | $650.00 | 01/24/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322014 |
| Principal investigator 1 | TOLMAR, INC. | $2,500.00 | 01/24/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322017 |
| Principal investigator 1 | TOLMAR, INC. | $765.00 | 01/24/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322021 |
| Principal investigator 1 | TOLMAR, INC. | $2,000.00 | 01/24/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322024 |
| Principal investigator 1 | TOLMAR, INC. | $2,500.00 | 01/24/2025 | Non-covered Recipient Entity FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC. | TOL2506A | No dispute reported | 06/30/2026 | 1237322283 |